Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies Review

Industry Collaboration International Collaboration

cited authors

  • Hirsch, Fred R., Kerr, Keith M., Bunn, Paul A., Jr., Kim, Edward S., Obasaju, Coleman, Perol, Maurice, Bonomi, Philip, Bradley, Jeffrey D., Gandara, David, Jett, James R., Langer, Corey J., Natale, Ronald B., Novello, Silvia, Paz-Ares, Luis, Ramalingam, Suresh S., Reck, Martin, Reynolds, Craig H., Smit, Egbert F., Socinski, Mark A., Spigel, David R., Stinchcombe, Thomas E., Vansteenkiste, Johan F., Wakelee, Heather, Thatcher, Nick

funding text

  • The concepts addressed in this article were originally discussed at a meeting convened by Eli Lilly and Company that discussed topics for physician and patient education on SqCLC for which participants, including some of the authors on this publication, received an honorarium. The authors received no payment in relation to the development of this publication, which was developed separately from the meeting. Medical writing assistance was funded by Eli Lilly and Company. Dr Hirsch has acted as a consultant/advisor to Bristol-Myers Squibb, Lilly, Pfizer, Merck, Ventana, and Roche/Genentech, and has received research funding from Bristol-Myers Squibb, Amgen, and Lilly/ImClone. Dr Kerr reports lecture fees and/or consultancy fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche, and Roche Diagnostics. Dr Bunn has received personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Merck, Roche/Genentech, Novartis, Pfizer, and Clovis. Dr Obasaju is an employee of Lilly. Dr Perol has acted as a consultant/advisor to AstraZeneca, Boehringer Ingelheim, Lilly, and Roche, and received nonfinancial support from Roche. Dr Bonomi has acted as a consultant/advisor to Lilly, has received honoraria from, and acted as a consultant/advisor to, AstraZeneca, Bristol-Myers Squibb, and Merck, and has received honoraria from Celgene, Pfizer, and Roche Genentech for safety/data monitoring committees. Dr Bradley has received grants from ViewRay and Mevion Medical Systems, has acted as an advisor to ViewRay and Varian, and has received honoraria from AstraZeneca. Dr Gandara has acted as a consultant/advisor to Lilly and Merck. Dr Jett is Chief Medical Officer of Oncimmune, LLC. Dr Langer has received honoraria from, and acted as a consultant/advisor to, Ariad, Boehringer Ingelheim, Celgene, Clovis, Lilly, Merck, and Roche/Genentech. Dr Novello has participated in speaker bureaus for Boehringer Ingelheim, Merck, AstraZeneca, Bristol-Myers Squibb, and Roche. Dr Paz-Ares has received personal fees from AstraZeneca, Bristol-Myers Squibb, Clovis, Lilly, Roche, Novartis, Merck, Clovis Oncology, Amgen, and Pfizer. Dr Ramalingam has acted as a consultant/advisor to Amgen, AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, and Novartis. Dr Reck has acted as a consultant/advisor to, and has participated in speaker bureaus for, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck, Merck Sharp & Dohme, Pfizer, F. Hoffmann-La Roche, and Celgene. Dr Reynolds has received personal fees from Lilly, Genentech, Boehringer Ingelheim, AstraZeneca, and Celgene. Dr Smit has received research grants from AstraZeneca, Bristol-Myers Squibb, Roche, and Genentech, and has served as a consultant/advisor for Lilly, AstraZeneca, Bristol-Myers Squibb, Bayer, Merck Sharp & Dohme, Pfizer, Novartis, and Roche. Dr Socinski has acted as a consultant/advisor to Lilly. Dr Stinchcombe has acted as a consultant for AstraZeneca, Takeda, and Novartis, and has received research funding from Takeda, Genentech, and Bristol-Myers Squibb. Dr Vansteenkiste has received research funding from AstraZeneca and Merck Sharp & Dohme, has acted as an advisor to Apotex, AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, and Novartis, and has been a lecturer for AstraZeneca, Lilly, Merck Sharp & Dohme, and Novartis. Dr Wakelee has acted as a consultant/advisor to Novartis, ACEA, Pfizer, and Peregrine, and has received research funding from AstraZeneca, Bristol-Myers Squibb, Celgene, Lilly, MedImmune, Novartis, Pfizer, Roche/Genentech, Gilead, and Xcovery. Dr Thatcher has received personal fees from Amgen, Celgene, OncoGenex, AstraZeneca, Roche/Genentech, and Otsuka, and has acted as a consultant/advisor to Lilly. The remaining authors have stated that they have no conflicts of interest.

abstract

  • Patients with nonesmall-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced nonesmall-cell lung cancer, with a focus on SqCLC. (C) 2018 The Authors. Published by Elsevier Inc.

authors

Publication Date

  • July 1, 2018

webpage

published in

category

start page

  • 331

end page

  • 339

volume

  • 19

issue

  • 4

WoS Citations

  • 0

WoS References

  • 84